Neoadjuvant Lenvatinib and Pembrolizumab for IVC Tumor Thrombus
Status:
Not yet recruiting
Trial end date:
2025-05-01
Target enrollment:
Participant gender:
Summary
This study will be evaluating safety and efficacy of the combination of lenvatinib and
pembolizumab neoaadjuvant therapy prior to surgical resection of locally advanced renal cell
carcinoma with IVC tumor thrombus.